Fill in your contactinformation to download the whitepaper

Whitepaper consent
Newsletter consent
News & insights
|
HERAN invests in Fluidic Sciences to support the expansion of its high‑performance microfluidics platforms for biologics discovery and development

HERAN invests in Fluidic Sciences to support the expansion of its high‑performance microfluidics platforms for biologics discovery and development

April 9, 2026 - Royston (UK)

HERAN is pleased to announce its second investment of HERAN HealthTech Fund II: Fluidic Sciences, a UK‑based life sciences tools company developing next‑generation microfluidics technologies for antibody discovery, cell line development, cell engineering and biophysical analysis

WHY HERAN INVESTS IN FLUIDIC SCIENCES

HERAN has a strong conviction in Fluidic Sciences’ technology and execution capability, driven by two mature, technically de-risked product lines with long-standing validation and a highly experienced team with the ability to scale valuable assets. Fluidics Science’s workflow reduces timelines, increases hit-quality and accelerates development, ultimately helping innovative treatments reach patients sooner.

Fluidic Sciences_Value proposition: Click image to view in full resolution
Fluidic Sciences_Value proposition: Click image to view in full resolution

Fluidic Sciences brings together the technologies and know‑how of SphereBio and Fluidic Analytics. Under the leadership of a seasoned team with deep operational experience in the life sciences tools sector, the Company has rapidly strengthened and consolidated two high‑value complementary technology platforms. This will enable the Company to serve a growing customer base with a technically validated platform.

Fluidic Sciences develops high‑throughput microfluidics systems for single‑cell functional screening and in‑solution biomolecular characterisation. Its flagship Cyto‑Mine® and Cyto‑Mine Chroma™ platforms integrate single‑cell screening, sorting, and monoclonality verification in one instrument. The Fluidity One‑M® platform measures biomolecular interactions in solution using Microfluidic Diffusional Sizing, enabling accurate affinity and binding‑site analysis without immobilisation artefacts. Together, these technologies form a differentiated workflow designed to improve the speed, efficiency and quality of biologics research.

The Board of Directors of Fluidic Sciences includes Mark Gilligan (Executive Chairman), David Newble, and Andrew Lovatt. The management team is led by James Wilkinson (CEO), Andrew Lovatt (COO), and Richard Hammond (CTO).

Fluidic Sciences brings together two highly validated technologies that directly address the bottlenecks we consistently see in biologics R&D. We are particularly impressed by the maturity and deep connectivity of the team, which combines decades of experience in scaling life science tools businesses. We are excited to partner with them as they drive disciplined commercial expansion and build a category‑defining platform in this space.

Mercedes Tuin, Partner at HERAN Partners and new member of the Board of Directors

Fluidic Sciences aims to give scientists unmatched insight at both the single‑cell and molecular levels. Bringing together the Cytomine and Fluidity platforms allows us to deliver a powerful, integrated workflow that raises the bar for speed, data quality and ease of use in biologics discovery.

Mark Gilligan, Chairman of the Board of Directors 

We’ve followed this technology for years and believe Fluidic Sciences is uniquely positioned to lead the next wave of microfluidics‑enabled discovery tools. The combination of technical depth, strong IP and proven customer demand makes this an exceptional opportunity.

Austin Duke, Managing Director at BroadOak Capital Partners

Fluidity One M
Fluidity One M

 

Cyto Mine
Cyto Mine

 

Download the press release (ENG)

HERAN Partners invests in Fluidic Sciences to support the expansion of its high‑performance microfluidics platforms for biologics discovery and development

Co-investors

BroadOak Capital

BroadOak Capital Partners is a life science focused, boutique financial institution that provides direct investment and investment banking services to companies in the research tools and consumables, diagnostics, and biopharma services sectors. BroadOak has led or participated in investments in more than 75 companies across multiple funds and investment vehicles and has advised on over 50 M&A transactions.
Back to top